CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP issued a shareholder-solicitation notice reminding CAPR investors of a pending securities class action alleging Exchange Act Sections 10(b) and 20(a) violations, with a lead plaintiff deadline of September 28, 2026. The complaint alleges Capricor changed the statistical analysis plan for its Deramiocel clinical data without FDA agreement before resubmitting its Biologics License Application, creating claimed risk the agency would not approve the BLA. The class period runs December 17, 2025 through July 26, 2026, and the class has not yet been certified.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.